Literature DB >> 33564935

Noninvasive prenatal detection of fetal sex chromosome abnormalities using the semiconductor sequencing platform (SSP) in Southern China.

Jiexia Yang1,2, Yaping Hou1,2, Fangfang Guo1,2, Haishan Peng1,2, Dongmei Wang1,2, Yi Li1,2, Haoxin Oy1,2, Yixia Wang1,2, Jian Lu1,2, Aihua Yin3,4.   

Abstract

BACKGROUND: Noninvasive prenatal testing (NIPT) has been widely used to screen for fetal aneuploidies, including fetal sex chromosome aneuploidies (SCAs). However, there is less information on the performance of NIPT in detecting SCAs.
METHODS: A cohort of 47,800 pregnancies was recruited to review the high-risk NIPT results for SCAs. Cell-free fetal DNA (cffDNA) was extracted and sequenced. All NIPT high-risk cases were recommended to undergo invasive prenatal diagnosis for karyotyping analysis and chromosome microarray analysis (CMA).
RESULTS: A total of 238 high-risk cases were detected by NIPT, including 137 cases of 45,X, 27 cases of 47,XXX, and 74 cases of 47,XYY/47,XXY. Prenatal diagnosis, including karyotyping analysis and CMA, was available in 170 cases. The positive predictive value (PPV) was 30.00% for 45,X, 70.58% for 47,XXX, and 81.13% for 47,XYY/47,XXY. In addition, 13 cases of sex chromosome mosaicism and 9 cases of sex chromosome CNVs were incidentally found in this study.
CONCLUSION: Our study showed that NIPT was reliable for screening SCAs based on a large sample, and it performed better in predicting sex chromosome trisomies than monosomy X. Our study will provide an important reference for clinical genetic counseling and further processing of the results.

Entities:  

Keywords:  Copy number variations (CNVs); Mosaicism; Noninvasive prenatal test (NIPT); Positive predictive values (PPVs); Sex chromosome aneuploidies (SCAs)

Mesh:

Year:  2021        PMID: 33564935      PMCID: PMC7910337          DOI: 10.1007/s10815-020-02056-2

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  27 in total

1.  Trophoblastic oxidative stress and the release of cell-free feto-placental DNA.

Authors:  May Lee Tjoa; Tereza Cindrova-Davies; Olivera Spasic-Boskovic; Diana W Bianchi; Graham J Burton
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

2.  Prenatal diagnosis of sex chromosome aneuploidies: experience at a mainland Chinese hospital.

Authors:  C Liao; C X Yi; D Z Li
Journal:  J Obstet Gynaecol       Date:  2013-11       Impact factor: 1.246

3.  Positive effects of early androgen therapy on the behavioral phenotype of boys with 47,XXY.

Authors:  Carole Samango-Sprouse; Emily J Stapleton; Patrick Lawson; Francie Mitchell; Teresa Sadeghin; Sherida Powell; Andrea L Gropman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2015-05-01       Impact factor: 3.908

4.  Screening for Sex Chromosome Aneuploidy by Cell-Free DNA Testing: Patient Choice and Performance.

Authors:  Elisa Bevilacqua; Elena Ordóñez; Ivan Hurtado; Laura Rueda; Eléonora Mazzone; Vincenzo Cirigliano; Jacques C Jani
Journal:  Fetal Diagn Ther       Date:  2017-08-23       Impact factor: 2.587

5.  Screening, prenatal diagnosis, and prenatal decision for sex chromosome aneuploidy.

Authors:  Yong Xu; Liyuan Chen; Yang Liu; Ying Hao; Zhiyong Xu; Liyanyan Deng; Jiansheng Xie
Journal:  Expert Rev Mol Diagn       Date:  2019-05-13       Impact factor: 5.225

6.  Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing.

Authors:  Yanlin Wang; Yan Chen; Feng Tian; Jianguang Zhang; Zhuo Song; Yi Wu; Xu Han; Wenjing Hu; Duan Ma; David Cram; Weiwei Cheng
Journal:  Clin Chem       Date:  2013-11-05       Impact factor: 8.327

7.  The impact of prenatally diagnosed Klinefelter Syndrome on obstetric and neonatal outcomes.

Authors:  Sarah K Dotters-Katz; Whitney M Humphrey; Kayli L Senz; Vanessa R Lee; Brian L Shaffer; Aaron B Caughey
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2016-06-09       Impact factor: 2.435

8.  Overall evaluation of the clinical value of prenatal screening for fetal-free DNA in maternal blood.

Authors:  Bin Yu; Bei-Yi Lu; Bin Zhang; Xiao-Qing Zhang; Ying-Ping Chen; Qin Zhou; Jian Jiang; Hui-Yan Wang
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

9.  Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China.

Authors:  Yanhui Liu; Hailiang Liu; Yi He; Wanfang Xu; Qiulin Ma; Yuzhen He; Wei Lei; Guoquan Chen; Zheng He; Jiayi Huang; Jianan Liu; Yuanru Liu; Quanfei Huang; Fubing Yu
Journal:  Hum Genomics       Date:  2020-06-05       Impact factor: 4.639

10.  Application of Non-Invasive Prenatal Tests in Serological Preclinical Screening for Women with Critical-Risk and Low-Risk Pregnancies but Abnormal Multiple of the Median Values.

Authors:  Lianli Yin; Yinghua Tang; Qing Lu; Minghe Jiang; Aiping Pan; Xu Zhu
Journal:  Clin Lab       Date:  2020-07-01       Impact factor: 1.138

View more
  2 in total

1.  Clinical Application of Noninvasive Prenatal Testing for Sex Chromosome Aneuploidies in Central China.

Authors:  Ganye Zhao; Peng Dai; Conghui Wang; Lina Liu; Xuechao Zhao; Xiangdong Kong
Journal:  Front Med (Lausanne)       Date:  2022-01-26

2.  A Critical Evaluation of Validation and Clinical Experience Studies in Non-Invasive Prenatal Testing for Trisomies 21, 18, and 13 and Monosomy X.

Authors:  Zachary Demko; Brittany Prigmore; Peter Benn
Journal:  J Clin Med       Date:  2022-08-15       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.